Abstract
Acute myeloid leukemia (AML) with FLT3-mutation carries a poor prognosis, and allogeneic stem cell transplantation (allo-SCT) is recommended at first complete remission (CR1). We assessed 462 adults (median age 50 years) with FLT3-mutated AML allografted between 2010 and 2015 from a matched related (40%), unrelated (49%), or haploidentical donor (11%). The median follow-up of alive patients was 39 months. Day-100 acute graft versus host disease (GVHD) grades II–IV and III–IV were encountered in 26% and 9%, whereas the 2-year incidence of chronic and extensive chronic GVHD were 34% and 16%, respectively. The 2-year incidences of relapse and nonrelapse mortality were 34% and 15%, respectively. The 2-year leukemia-free survival, overall survival (OS), and GVHD relapse-free survival (GRFS) were 51%, 59%, and 38%, respectively. In multivariate analysis, NPM1-mutation, transplantation in CR1, in vivo T-cell depletion, and posttransplant sorafenib improved OS, whereas more than one induction (late CR1) negatively affected OS. Similarly, NPM1-mutation, a haploidentical donor, T-cell depletion, and sorafenib maintenance improved GRFS, whereas late CR1 or persistent disease negatively affected it. In conclusion, FLT3-mutated AML remains a challenge even following allo-SCT. In vivo T-cell depletion and posttransplant sorafenib significantly improve OS and GRFS, and may be considered as standard of care.
Article PDF
Avoid common mistakes on your manuscript.
References
Papaemmanuil, E, Gerstung, M, Bullinger, L, Gaidzik, VI, Paschka, P, Roberts, ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 2016;374(23);2209–21.
Gilliland, DG, Griffin, JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002;100(5);1532–42.
Levis, M, Small, D. FLT3: ITDoes matter in leukemia. leukemia 2003;17(9);1738–52.
Stirewalt, DL, Radich, JP. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003;3(9);650–65.
Kottaridis, PD, Gale, RE, Frew, ME, Harrison, G, Langabeer, SE, Belton, AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98(6);1752–9.
Frohling, S, Schlenk, RF, Breitruck, J, Benner, A, Kreitmeier, S, Tobis, K, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002;100(13);4372–80.
Thiede, C, Steudel, C, Mohr, B, Schaich, M, Schakel, U, Platzbecker, U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99(12);4326–35.
Rombouts, WJ, Blokland, I, Lowenberg, B, Ploemacher, RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000;14(4);675–83.
Bornhauser, M, Illmer, T, Schaich, M, Soucek, S, Ehninger, G, Thiede, C, et al. Improved outcome after stem-cell transplantation in FLT3/ITD-positive AML. Blood 2007;109(5);2264–5.
DeZern, AE, Sung, A, Kim, S, Smith, BD, Karp, JE, Gore, SD, et al. Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant 2011;17(9);1404–9.
Dohner, H, Estey, E, Grimwade, D, Amadori, S, Appelbaum, FR, Buchner, T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4);424–47.
Sakaguchi, M, Yamaguchi, H, Najima, Y, Usuki, K, Ueki, T, Oh, I, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv 2018;2(20); 2744–54.
Brunet, S, Labopin, M, Esteve, J, Cornelissen, J, Socie, G, Iori, AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol 2012;30(7);735–41.
Schmid, C, Labopin, M, Socie, G, Daguindau, E, Volin, L, Huynh, A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood 2015;126(17);2062–9.
Antar, A, Otrock, ZK, El-Cheikh, J, Kharfan-Dabaja, MA, Battipaglia, G, Mahfouz, R, et al. Inhibition of FLT3 in AML: a focus on sorafenib. Bone Marrow Transplant 2017;52(3);344–51.
Rollig, C, Serve, H, Huttmann, A, Noppeney, R, Muller-Tidow, C, Krug, U, et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015;16(16);1691–9.
Macdonald, DA, Assouline, SE, Brandwein, J, Kamel-Reid, S, Eisenhauer, EA, Couban, S, et al. A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186. Leuk Lymphoma 2013;54(4); 760–6.
Serve, H, Krug, U, Wagner, R, Sauerland, MC, Heinecke, A, Brunnberg, U, et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31(25);3110–8.
Borthakur, G, Kantarjian, H, Ravandi, F, Zhang, W, Konopleva, M, Wright, JJ, et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haemato-logica 2011;96(1);62–8.
Metzelder, SK, Schroeder, T, Lubbert, M, Ditschkowski, M, Gotze, K, Scholl, S, et al. Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. Eur J Cancer 2017;86; 233–9.
Cortes, JE, Kantarjian, H, Foran, JM, Ghirdaladze, D, Zodelava, M, Borthakur, G, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 2013;31(29);3681–7.
Levis, MJ, Perl, AE, Altman, JK, Cortes, JE, Ritchie, EK, Larson, RA, et al. Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML). J Clin Oncol 2015;33(15 Suppl);7003.
Leung, AY, Man, CH, Kwong, YL. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia. Leukemia 2013;27(2);260–8.
Thol, F, Schlenk, RF, Heuser, M, Ganser, A. How I treat refractory and early relapsed acute myeloid leukemia. Blood 2015;126(3);319–27.
Winkler, J, Rech, D, Kallert, S, Rech, J, Meidenbauer, N, Roesler, W, et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report. Leuk Res 2010;34(10);e270–e2.
Sharma, M, Ravandi, F, Bayraktar, UD, Chiattone, A, Bashir, Q, Giralt, S, et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011;17(12); 1874–7.
Metzelder, SK, Schroeder, T, Finck, A, Scholl, S, Fey, M, Gotze, K, et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses. Leukemia 2012;26(11);2353–9.
Rautenberg, C, Nachtkamp, K, Dienst, A, Schmidt, PV, Heyn, C, Kondakci, M, et al. Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT. Eur J Haematol 2017;98(4);348–54.
Oran, B, Cortes, J, Beitinjaneh, A, Chen, HC, de Lima, M, Patel, K, et al. Allogeneic transplantation in first remission improves outcomes irrespective of FLT3-ITD allelic ratio in FLT3-ITD-positive acute myelogenous leukemia. Biol Blood Marrow Transplant 2016;22(7);1218–26.
Battipaglia, G, Ruggeri, A, Massoud, R, El Cheikh, J, Jestin, M, Antar, A, et al. Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. Cancer 2017;123(15);2867–74.
Chen, YB, Li, S, Lane, AA, Connolly, C, Del Rio, C, Valles, B, et al. Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 2014;20(12);2042–8.
Brunner, AM, Li, S, Fathi, AT, Wadleigh, M, Ho, VT, Collier, K, et al. Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 2016;175(3);496–504.
Antar, A, Kharfan-Dabaja, MA, Mahfouz, R, Bazarbachi, A. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 2015;15(5);298–302.
Stone, RM, Mandrekar, SJ, Sanford, BL, Laumann, K, Geyer, S, Bloomfield, CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 2017;377(5);454–64.
Bacigalupo, A, Ballen, K, Rizzo, D, Giralt, S, Lazarus, H, Ho, V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant 2009;15(12); 1628–33.
Przepiorka, D, Weisdorf, D, Martin, P, Klingemann, HG, Beatty, P, Hows, J, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995;15(6);825–8. https://www.ncbi.nlm.nih.gov/pubmed/7581076
Flowers, ME, Kansu, E, Sullivan, KM. Pathophysiology and treatment of graft-versus-host disease. Hematol Oncol Clin North Am 1999;13(5);1091–112, viii–ix.
Grimwade, D, Hills, RK, Moorman, AV, Walker, H, Chatters, S, Goldstone, AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116(3);354–65.
Ruggeri, A, Labopin, M, Ciceri, F, Mohty, M, Nagler, A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant 2016;51(4);610–1.
Gale, RE, Hills, R, Kottaridis, PD, Srirangan, S, Wheatley, K, Burnett, AK, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005;106(10);3658–65.
Meshinchi, S, Arceci, RJ, Sanders, JE, Smith, FO, Woods, WB, Radich, JP, et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006;108(1);400.
DeZern, AE, Sung, A, Kim, S, Tsai, H-L, Kowalski, J, Smith, BD, et al. Patients with FLT3/ITD AML may benefit from allogeneic transplant in first remission: outcomes from a consecutive series of patients at a single institution. Blood 2010;116(21);2172.
Sengsayadeth, SM, Jagasia, M, Engelhardt, BG, Kassim, A, Strickland, SA, Goodman, S, et al. Allogeneic stem cell transplantation for FLT3/ITD positive acute myeloid leukemia in CR1: implication for personalized therapy to prevent early relapses. Biol Blood Marrow Trans 2012;18(2);S332–S3.
Kayser, S, Döhner, K, Krauter, J, Casper, J, Horst, HA, Held, G, et al. Impact of allogeneic transplantation from matched related and unrelated donors on clinical outcome in younger adult AML patients with FLT3 internal tandem duplications. Blood 2012;116(21);909. Accessed March 22, 2019. Retrieved from https://www.bloodjournal.org/content/116/21/909.
Hemmati, P, Theis, T, Vuong, LG, le Coutre, PD, Dorken, B, Arnold, R. Allogeneic stem cell transplantation for cytogenetically normal acute myeloid leukemia: impact Of FLT3 and NPM1 mutational status. Blood 2013;122;21.
Liegel, J, Courville, E, Sachs, Z, Ustun, C. Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect. Haematologica 2014;99(11);e222–e4.
Deol, A, Sengsayadeth, S, Ahn, KW, Wang, HL, Aljurf, M, Antin, JH, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer 2016;122(19);3005–14.
Poire, X, Labopin, M, Maertens, J, Yakoub-Agha, I, Blaise, D, Ifrah, N, et al. Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). J Hematol Oncol 2017; 10(1);20.
Labouré, G, Dulucq, S, Vigouroux, S, Lippert, É, Pigneux, A, Tabrizi, R, et al. Potent graft-versus-leukemia effect after Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) as post-remission therapy for intermediate-risk de-novo Acute Myeloid Leukemia (AML) with FLT3-ITD genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD. Blood 2011;118(21);4129.
Gale, RE, Green, C, Allen, C, Mead, AJ, Burnett, AK, Hills, RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111(5);2776–84.
Gaballa, S, Saliba, R, Oran, B, Brammer, JE, Chen, J, Rondon, G, et al. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol 2017;92(4);331–7.
Kharfan-Dabaja, MA, Labopin, M, Polge, E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncology 2018;4;1245–53.
Shimoni, A, Volchek, Y, Koren-Michowitz, M, Varda-Bloom, N, Somech, R, Shem-Tov, N, et al. Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.Cancer 2015;121(6);863–71.
Ottmann, OG, Pfeifer, H. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Hematol Am Soc Hematol Educ Program 2009;2009;371–81.
Schlenk, RF, Fiedler, W, Salih, HR, Wulf, G, Thol, F, Kündgen, A, et al. Impact of age and midostaurin-dose on response and out-comeinacute myeloid leukemia with FLT3-ITD: interim-analyses of the AMLSG 16–10 trial. Blood 2016;128(22);449.
Burchert, A. Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. In ASH Annual Meeting, San Diego, 2018.
Tschan-Plessl, A, Halter, JP, Heim, D, Medinger, M, Passweg, JR, Gerull, S. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. Ann Hematol 2015;94(11); 1899–05.
Yokoyama, H, Lundqvist, A, Su, S, Childs, R. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 2010;116(15);2858–9.
Mathew, NR, Baumgartner, F, Braun, L, O’Sullivan, D, Thomas, S, Waterhouse, M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018;24(3);282–91.
Versluis, J, In ‘t Hout, FE, Devillier, R, van Putten, WL, Manz, MG, Vekemans, MC, et al. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio. Leukemia 2017;31(1);26–33.
Schlenk, RF, Kayser, S, Bullinger, L, Kobbe, G, Casper, J, Ringhoffer, M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood 2014;124(23);3441–9.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Peer review is under the responsibility of IACH
Rights and permissions
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).
About this article
Cite this article
Bazarbachi, A., Labopin, M., Battipaglia, G. et al. Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clin Hematol Int 1, 58–74 (2019). https://doi.org/10.2991/chi.d.190310.001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.2991/chi.d.190310.001